Moderna. has been granted a patent for methods to treat solid tumors and lymphomas using LNP-encapsulated mRNAs that encode human OX40L, IL-23, and IL-36?. The method includes intratumoral injection of these mRNAs, potentially targeting conditions like triple negative breast cancer and melanoma. GlobalData’s report on Moderna gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Moderna, mRNA delivery lipid nanoparticles was a key innovation area identified from patents. Moderna's grant share as of June 2024 was 24%. Grant share is based on the ratio of number of grants to total number of patents.